OREANDA-NEWS. OJSC "VEROPHARM" [RTS:VRPH, MICEX:VFRM] announces its unaudited financial results for 9 months of 2013 in accordance with the International Financial Reporting Standards (IFRS).

SALES

Sales for 9 months of 2013 amounted to RUR 3,578.1 mln. The share of product segments in OJSC “Veropharm” sales is as follows:

Group of pharmaceutical products

Rx drugs sales amounted to RUR 2,596.7 mln. The Rx drugs sales made 72.6% of total sales of the Company;

OTC drugs sales amounted to RUR 569.2 mln. The OTC drugs sales made 15.9% of total sales of the Company.

Traditional drugs sales amounted to RUR 12.5 mln. The traditional drugs sales made 0.3% of total sales of the Company.

Group of non-pharmaceutical products

Non-pharmaceutical products sales made RUR 399.7 mln, which corresponds to 11.2% of total sales of the Company.

Under the Federal Reimbursement Program (FRP) Veropharm's sales amounted to RUR 27.1 mln according to the results of 9 months of 2013, which corresponds to 0.8% of the Company's total sales.

The Russian Federation is the main market and ensures 94.0% of the Company's sales. During 9 months of 2013 the Company has exported 6.0% of its products.

PROFIT

For 9 months of 2013 the gross profit of OJSC “Veropharm” amounted to RUR 2,222.0 mln. The gross profit ratio 9 months of 2013 made 62.1%. The gross profit ratio of the segments of OJSC “Veropharm” is as stated:

Group of pharmaceutical products

In relation to Rx drugs it made 62.3% for 9 months of 2013;

In relation to OTC drugs it made 67.0% for 9 months of 2013;

In relation to traditional products it made 44.8% for 9 months of 2013.

Group of non-pharmaceutical products

In relation to non-pharmaceutical products it made 54.1% for 9 months of 2013.

For 9 months of 2013 EBITDA amounted to RUR 951.3 mln. EBITDA margin made 26.6%.

Operating profit for 9 months of 2013 made RUR 857.9 mln. Operating profit margin made 23.9% for 9 months of 2013.

Net profit for the reporting period amounted to RUR 465.4 mln. Net profit margin made 13.0%.

FACILITIES INVESTMENTS

For 9 months of 2013 the amount of investments assigned for modernization and equipment of the main production facilities of the Company made RUR 1,976 mln.

DEBT

As at September 30, 2013 the debt of OJSC “Veropharm” amounted to RUR 2,529.8 mln, which makes no more than 25% of the Company's net assets value.